Publication|Articles|November 20, 2026

Evidence-Based Oncology

  • Patient-Centered Oncology Care 2026
  • Volume 32
  • Issue Spec 15

Reimagine Care Pitches a “Travel Desk” for Patients Between Cancer Visits

Author(s)Mary Caffrey
Fact checked by: Yasmeen Qahwash
Listen
0:00 / 0:00

Key Takeaways

  • Centralized, AI-supported navigation aims to route symptom calls to the right site and clinician across diverse practice geographies, countering system-centered workflows.
  • The operational framework requires capture, understand, prioritize, act, and document; incomplete execution limits survival and utilization gains seen with PRO symptom monitoring trials.
SHOW MORE

John Elliott, of Reimagine Care, outlined a model that pairs AI-supported triage with oncology-trained nurses, and the CEO of a large Texas practice described how the partnership has grown to include patients receiving CAR T-cell therapy.

When a patient has cancer, care teams do their best to carefully map an itinerary. But like any journey, things don’t always go according to plan.

What happens when a patient who lives alone spikes a fever at 6 pm on a Thursday, 9 days into their second cycle of therapy?

That was the question John Elliott, head of growth, US, for Reimagine Care, asked the audience at the 2026 Patient-Centered Oncology Care (PCOC) conference in Nashville, Tennessee. Reimagine Care was the second company to present during OncoVenture, a portion of the PCOC program that allows newer companies to showcase how they are improving cancer care delivery.

Elliott opened by asking the PCOC cochairs how their organizations handle that moment. Sucharu “Chris” Prakash, MD, director of quality services and chair of the Medical Oncology Quality Committee at Texas Oncology, went first.

“We are the largest practice in the country,” he said. “So we [have] 1000 providers spread all over the state of Texas—diverse geographic [and] socioeconomic settings, large comprehensive cancer centers, all the way down to small rural satellite clinics.” To manage care across these settings, the practice now uses a centralized, artificial intelligence (AI)-supported navigation platform that routes calls “to the right facility, the right nurse.”

By contrast, the nurses answering Mayo Clinic’s 24/7 central line are not oncology specialists, said Scott Soefje, PharmD, MBA, BCOP, director of pharmacy cancer care services at Mayo Clinic. “One of the biggest problems in health care these days is that the itineraries around patients, the things we do for patients, are not centered around the patients; they’re centered around what’s convenient for the health care systems and for providers,” he said.

A Travel Desk for Oncology

Elliott framed that gap with an airline metaphor. “When a flight is canceled, a traveler is not simply handed a list of phone numbers,” he said. Health care has built the treatment itinerary, he said, but not the function that responds when a patient departs from it.

Reimagine Care’s model rests on 5 steps: capture, understand, prioritize, act, and document. “You can do 1, you can do 2 well, but if you don’t do all 5 well, then you don’t get all of the outcomes,” Elliott said, citing the work of Ethan Basch, MD, MSc, of the University of North Carolina, whose randomized trial found that patients who self-reported symptoms during chemotherapy lived a median of 31.2 months vs 26.0 months with usual care.1

AI can sort different types of incoming information, but it has its limits. “I’m not talking about [a] clinical decision by the AI. It’s more around intent recognition and sifting through the information and…where it needs to go for the right appropriate person,” Elliott said.

Context matters. “A cough or a fever can be completely different from one patient to another,” he said. A low-grade cough may not trigger an alert in a patient taking paclitaxel, but it would in one taking the antibody-drug conjugate trastuzumab deruxtecan (Enhertu; AstraZeneca/Daiichi Sankyo), given the risk of interstitial lung disease.2

In the case Elliott presented, the patient had stage IV non–small cell lung cancer and was receiving carboplatin, pemetrexed, and pembrolizumab. Because her fever came inside the expected nadir window, it was escalated immediately as possible febrile neutropenia. She was seen at her practice’s clinic that evening, avoiding the emergency department (ED).

Reimagine Care’s oncology-trained nurses serve as an extension of a practice’s staff, Elliott said, rather than leaving a backlog of weekend MyChart messages for Monday morning. “We’re not adding to that. We’re dealing with those and addressing those in real time,” he said. According to the company, responses to a live clinician average 9 minutes, only 3% of encounters are escalated back to partner care teams, and an actuarial analysis in a Medicare population found a 77% reduction in ED visits.

The concept is poised for growth; in the weeks just ahead of PCOC, Reimagine Care was acquired by Cureety, a precision oncology company that supports 250 cancer centers and 100,000 patients in 5 countries.3

“Our Patients Love Remi”

Barry Russo, MBA, CEO of The Center for Cancer and Blood Disorders (CCBD) in Fort Worth, Texas, described his practice’s experience of working with Reimagine Care for more than 3 years.

“We were struggling to keep a consistent triage team in our practice,” Russo said. “Triage is a tough job, and listening to patients have problems all day long is not what people love to do. So we made the decision several years ago to sort of acquiesce our triage to the Reimagine Care central team. It’s gone incredibly well—way better than I thought it would.”

He singled out Remi, Reimagine Care’s AI assistant, which texts patients twice weekly to check how they are feeling. “I thought maybe our [older] patients would not want to get texts, but they love to get texts,” he said.

CCBD has expanded the service to include hematology and surgical patients, as well as those receiving bispecific antibodies; at the time of PCOC, the practice had administered chimeric antigen receptor (CAR) T-cell therapy to 5 patients. “It really has become a standard part of our practice. It doesn’t feel any different to us and our team,” Russo said.

Cochairs Ask for More Details

Soefje drilled down on how the company handles differing protocols. “What we want to do at Mayo Clinic and what the largest cancer center in Texas wants to do are 2 different things,” he said. “As we all know in health care, there are multiple ways to skin a cat.”

“You have to understand all the variables,” Elliott replied, including where each partner draws “that line in the sand” for escalation. Using the data to standardize toxicity management, he said, is “in the exploratory phase.”

Soefje also raised message fatigue among patients taking aromatase inhibitors for 5 years. “If we send a daily text every day for 5 years, going, ‘Did you take your med?’ at some point in time, people are going, ‘Yeah, no,’” he said.

References

  1. Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318(2):197-198. doi:10.1001/jama.2017.7156
  2. Powell CA, Modi S, Iwata H, et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022;7(4):100554. doi:10.1016/j.esmoop.2022.100554
  3. Cureety acquires Reimagine Care to build future of precision oncology care. News release. Cureety. September 2, 2026. Accessed November 11, 2026. https://reimaginecare.com/publications/cureety-acquires-reimagine-care/


Related to this article